Olivia Vizier

“All of a sudden, almost every person in the world almost knows this word: mRNA,” said Yochi Slonim, co-founder and CEO of Anima Biotech, a New Jersey-based company developing selective small-molecule mRNA drugs with its mRNA Lightning platform. 

A: Our greatest impact will be in the field of psychiatry, due to our bringing a precision medicine approach to the field for the first time. Today, psychiatric treatment only works for roughly one in three patients. 

Portage Biotech is leveraging its team’s longstanding experience in immuno-oncology (members have contributed to the development of several approved and in development CPIs) and treatment resistance to develop a series of novel combinations to help those not responding to the SOC. 

Ring’s research team has uncovered and characterized the world’s largest collection of commensal anelloviruses and is harnessing those best suited for specifically targeting a wide array of diseases with significant unmet needs. The unique biology of anelloviruses may indeed provide a foundation for an unparalleled new gene therapy platform and the resulting new class of

At just 10 months out of stealth, gene-editing startup SalioGen Therapeutics has lassoed a $115 million round with plans to double its team, build out its drug pipeline and move to a new, expanded facility.

As 2022 begins, Aptinyx is laying the groundwork to transition to a late-stage clinical, and one day commercial, company. At the same time, its senior leadership also is transitioning into new roles. Andy Kidd, M.D., takes on the role of CEO after stints as Aptinyx’s president and chief operating officer, and before that, chief commercial officer. Norbert

It was late 2015 when Lara Sullivan, M.D., first called me. At the time she was a VP at Pfizer and working closely with Freda Lewis-Hall, M.D., then the company’s chief medical officer. From their vantage point, they could see this tremendous pipeline flow of assets—along with what got funded — and what did not.

Mental health startup Cerebral has inked a partnership with Alto Neuroscience to bring clinical trials for depression to patients’ homes.

When she helped start MeiraGTx Holdings in 2015, CEO Zandy Forbes wanted to find a way to precisely control the output of genes implanted in people to fix genetic disorders. In an analyst meeting Wednesday, MeiraGTx unveiled that technology.

Scynexis sees a $300m-$400m commercial opportunity for the supplemental indication. A new therapeutic option is needed for oral step-down therapy because many Candida infections are resistant to oral fluconazole.

Douglas W. Blayney, MD, is a professor of medicine (oncology) at Stanford University and the former Medical Director of Stanford Cancer Center. He specializes in breast cancer treatment. He is particularly concerned about the quality and value of cancer care. In this video Dr. Blayney discusses the Phase 3 PROTECTIVE-2 TRIAL.

Sotio has been on a roll lately. The quiet Czech biotech based in Prague got a massive $315 million raise last week, and now the biotech announced today that it’s joined in on a collaboration with Merck to evaluate a combo of Sotio’s lead candidate SOT101 with Merck’s PD-1 antibody Keytruda.

Sotio Biotech has advanced its effort to become a major player in the solid tumor space. Days after raising $316 million, Sotio has unveiled a deal with Merck to use Keytruda in a clinical trial that is central to its plans for investing in the megaround. 

MeiraGTx has announced preliminary data from the ongoing Phase 1 AQUAx trial of AAV-hAQP1 for grade 2/3 radiation-induced xerostomia (RIX).

Cerevance is working to change that. Proprietarytechnology that accurately determines brain age andrelates it to Alzheimer’s, Parkinson’s, and other braindiseases is providing novel insights that inform therapeutic development

Durect focuses on eliminating the epigenetic faults that cause cells to become dysfunctional. Following this approach, Durect intends to generate drugs that can treat acute organ injury and chronic liver diseases.

Sotio is also working on earlier efforts, including BOXR1030, its next-gen CAR-T program for solid tumors expressing GPC3 and based on its so-called BOXR platform “that aims to enhance the fitness of T cells in the hostile tumor microenvironment,” according to the Prague-based company.

Last month, Jessie Jackson’s friends and family sang her happy birthday a little early. Jessie doesn’t turn 30 until Dec. 12, but for the past five years on the anniversary of her diagnosis, her parents have hosted a fundraiser. They weren’t taking any chances.

Pfizer must have liked what it saw in data presented by Cardiff Oncology for a challenger in KRAS-mutated cancers. The Big Pharma is putting up a $15 million equity investment in the biotech to help bankroll development of the drug. 

“Fountain is an example of a biotech company emerging as a direct result of basic research, in this case the biology of aging,” said Dr Rando, founder and chairman of Fountain. “The company’s screening and discovery platform is built upon foundational research showing that the age of a cell can be modulated by factors in

When you’re heading up a fledgling biotech out to make a name for yourself in the middle of a wild industry boom, there’s one sure way to differentiate yourself that’s bound to attract universal nods.

While anti-depressants and therapy have helped, Evanston-based biotech company Aptinyx have a pill in the pipeline that they hope will prevent the trauma that triggers PTSD.

Meet the second group of 14 executives being honored in 2021.

Orchestra BioMed presentedlong-term clinical results and ISH subgroup data from the MODERATO II trial of BackBeat Cardiac Neuromodulation Therapy in patients with hypertension and an indication for a pacemaker. The results demonstrated a mean reduction of 17.5 mmHg in office systolic blood pressure in all BackBeat CNT treated patients who completed 24-month follow-up.

In late 2017, Discovery Labs was at the brink of falling apart. The company’s investors pulled out after Aerosurf, its sole remaining asset being developed as a treatment for premature infants with respiratory distress syndrome, failed to meet its endpoints in a Phase IIb study.

One of the greatest recent innovations in cancer treatment, CAR T therapies have sent some patients into long-lasting remission, with speedier recoveries, due to the lack of aggressive chemotherapy involved. They are the darling of numerous biopharma companies, including Sorrento Therapeutics, Kite Pharma (Gilead), and Allogene Therapeutics.

Pharmacokinetics data on vurolenatide, a long-acting glucagon-like peptide-1 (GLP-1) being developed for short-bowel syndrome (SBS), suggest that the drug could be given twice monthly or less, an improvement over existing GLP-2 drugs, which must be given at least weekly.

Dutch biotech firm ProQR Therapeutics announced it had struck its own RNA-editing partnership with Eli Lilly and Company to develop therapies for liver and nervous system diseases.